ISRCTN67956295已完成未知
Prospective, open-label trial evaluating Outcomes of immediate implant-based Breast Reconstruction using an Acellular Dermal matrix (ADM) (POBRAD trial)
King's College of London (UK)0 个研究点目标入组 40 人开始时间: 2013年3月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
2013 results in https://doi.org/10.1016/j.ejso.2013.07.125 (added 30/01/2020)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Female
入选标准
- •1. Any person older than 18 years of age meeting the inclusion criteria are eligible to the study
- •2. All post-mastectomy patients undergoing immediate implant-based, breast reconstruction requiring lower pole cover
排除标准
- •1. Significant co-morbidities
- •2. Body mass index (BMI) >40
- •3. Locally advanced and/ or inflammatory breast cancer
- •4. Patients unable to provide informed consent to participate in trial
研究者
相似试验
进行中（未招募）
4 期
Stabilization of kidney function in patients diagnosed with primary immunoglobulin A nephropathy by treatment with a locally-acting corticosteroid formulation – budesonideISRCTN47722295Institutul Clinic Fundeni32
已完成
不适用
A randomised, open-label, multicentre, efficacy and safety study examining the effects on viral kinetics of all-trans retinoic acid (Tretinoin) (VESANOID®) in combination with pegylated interferon alpha-2a (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with genotype 1-chronic hepatitis C and non-response to a previous course of peg-interferon alpha/ribavirin combination (ATRACTION)Hepatitis CISRCTN00680126Johannes Gutenberg-University Mainz (Johannes Gutenberg-Universitat Mainz) (Germany)57
已完成
2 期
A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancerAdvanced oesophago-gastric cancerOesophago-gastric cancerCancerISRCTN65080435The Royal Marsden Hospital NHS Foundation Trust (UK)553
已完成
2 期
Randomized, open-label, prospective study to evaluate the safety and efficacy of sofosbuvir plus daclatasvir or ravidasvir in Egyptian adults with COVID-19COVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN21085622European Egyptian Pharmaceutical Industries (EEPI)120
已完成
3 期
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)Primary IgA NephropathyNCT04541043Calliditas Therapeutics AB119